Background: Here is no convincing active treatment for patients with PROC. Antiapoptotic bcl-2 proteins have been implicated in chemotherapy (CT) resistance. In preclinical studies, we demonstrated promising activity of Navitoclax, an anti-apoptotic inhibitor of Bcl-2 family, in ROC tumors, suggesting a potential action in platinum resistant pts. We conducted a multicentric phase II trial of Navitoclax monotherapy and reported modest efficacy (ESMO 2017, abstract #2269). Here we aimed to describe the relationship between Bcl-2 protein expression and response to Navitoclax; we also reported response to subsequent line of CT. Methods: Pts (N ¼ 46) with high grade serous PROC received oral Navitoclax (150 mg daily for 7 days followed by 250 mg daily) until disease progression or toxicity. All pts had a biopsy of relapsed disease before navitoclax initiation to assess the expression level of Bcl-2 proteins by histoimmunochemistry (IHC), as low, medium or high. We first evaluated the efficacy of Navitoclax for pts with high BIM level, then with high BIM expression combined with low Mcl-1 and/or phospho-ERK. Response to subsequent CT was also described. Results: 44 pts (with median of 4 prior lines) were assessable for efficacy: PFS was 50 days with 1 partial response (PR), 15 stable diseases (SD). IHC data were available for 35 pts. BIM was highly expressed in 9 pts, 4 of them with PR/SD (p ¼ 0.68). Among them, 7 had a low expression of Mcl-1 and/or phospho-ERK, of whom 4 with PR/SD, showing no evidence of relation with clinical response. After Navitoclax, 32 pts were retreated with CT: 4PR and 9SD were noted, including 11 pts with long response (6-13 months). Median delay from previous platinum-based treatment to subsequent CT was 9 months [2-23] for PR/SD pts. Especially, 12 pts received platinum after Navitoclax with high response rate (3PR/4SD, 58%), median delay from previous platinum-CT was 18 months. Conclusions: BIM expression, alone or combined with Mcl-1 and/or pERK, is not predictive of Navitoclax benefit. High proportion of PROC pts response to platinum rechallenge; the potential implication of Navitoclax needs further explorations. Other Bcl-2 family proteins (activator BH3-only BID and PUMA) expression may be more relevant. Background: Cervical cancer ranks first among gynecologic malignancies. Neoadjuvant chemotherapy combined with surgery is currently a recommended treatment for locally advanced cervical cancer, however the patient's prognosis is still poor and easy to recur even if the chemotherapy works significantly. We need more effective assessment method for local advanced cervical cancer. Therefore, we evaluated relationship between chemotherapeutic effect and prognosis on the expression of immunological biomarkers including CD4þ, CD8þ and Foxp3 pre-and post-neoadjuvant chemotherapy for locally advanced cervical cancer. Methods: CD4þ, CD8þ and Foxp3 expression by IHC in 45 cases of locally advanced (IB2-IIB) cervical cancer pre-and post-neoadjuvant chemotherapy, computer software was used to quantitatively analyzed. The relationship between IHC results and clinicopathological characteristics, chemotherapy efficacy, PFS and OS was analyzed by SPSS software.
Results: The expression of CD4, CD8 and Foxp3 in locally advanced cervical cancer before and after neoadjuvant chemotherapy was not related to patients' age and size of tumor (P > 0.05), which was related to FIGO staging and histological grade. The expression of CD4 and CD8 increased significantly after chemotherapy (P ¼ 0.016, P ¼ 0.009), while the expression of FoxP3 decreased significantly (P ¼ 0.002). There was a significant correlation between the expression of CD8 (P ¼ 0.005), Foxp3 (P ¼ 0.041) and PFS in locally advanced cervical cancer, while CD4 had no significant correlation (P ¼ 0.581). However, there is no significant correlation between OS and CD4 (P ¼ 0.686), CD8 (P ¼ 0.858) and Foxp3 (P ¼ 0.689).
Conclusions: CD4, CD8 and Foxp3 are associated with tumor staging and pathological grading in neoadjuvant chemotherapy for locally advanced cervical cancer, and the expression change of CD8 and Foxp3 before and after chemotherapy can be used as an independent prognostic indicator.
Legal entity responsible for the study: Wen Di. Background: Ovarian carcinoma has the highest mortality rate among gynecologic malignancies. Primary drug resistance and multi-drug resistance are major clinical obstacles to treatment and is the main reason for the dismal 5-year survival rate of patients. Apatinib is independently developed in China as an effective small-molecule tyrosine kinase inhibitor. It mainly functions by competitively blocking the binding of VEGF with VEGFR-2 and auto-phosphorylation of VEGFR-2, thereby inhibiting the function of VEGF in stimulating endothelial cell proliferation and migration and reducing microvascular density to elicit its anti-tumor effects.
Methods: This study is a prospective, open label, single-arm clinical trial aimed to evaluate the efficacy and safety of apatinib mesylate as treatment after failure of second-line chemotherapy in patients with advanced epithelial ovarian cancer. The study enrolled 20 patients, and 17 were evaluated. Patients received an oral dosage of apatinib (500 mg or 250 mg) once daily for 28 days as an observation cycle. The efficacy of the treatment was evaluated after three treatment cycles. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse events (AEs) were assessed. Results: After 3 cycles of treatment, 6 (35.3%) and 2 (11.8%) patients achieved partial response (PR) and stable disease (SD), respectively. The ORR and DCR were 35.3% and 47.1%, respectively. The efficacy of apatinib was not significantly different between patients with initial dosages of 500 mg (ORR, 30%; DCR, 30%) and 250 mg (ORR, 42.8%; DCR, 71.4%). The median PFS was 2.2 months (95% confidence interval (CI), 1.0m-8.9m) and the median OS was 6.3months (95% CI, 1.5m-12.8m). The most common AEs were hypertension (70.6%), hand-foot syndrome (52.9%), and oral mucosa damage (35.3%).
Conclusions: In conclusion, oral apatinib treatment was efficacious, safe, and had no serious adverse effects in patients with advanced EOC who failed second-line chemotherapy. 
